Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: March Update

Performance overview
Value at beginning of month: $98,120.95
Value at end of month: $97,541.67
Month over month change: -0.59%
Total CAGR: -9.48%

Related indices, monthly change
NASDAQ: +1.48%
IVV (iShares Core S&P 500): -0.32%
IBB (iShares NASDAQ Biotechnology Index): -1.33%
MXI (iShares Global Materials): +0.96%
VEGI (iShares MSCI Global Agriculture Producers): -0.35%

Individual performances

Intrexon being down 10% in March dragged the index to negative returns, with no companies exhibiting large gains. There were several agriculture companies down over 20%, including AquaBounty, Terravia, and Arcadia. Bioamber was down another 31% this month, and it has been down over 50% this year.

Dollar amounts in millions

Dollar amounts in millions

Many companies released their 2016 fourth quarter and annual earnings during March. Only one of these companies, Novozymes, made a profit in 2016. Last year only half of the companies increased their revenue, and just over half increased their income. The average price to sales multiple for the index is around 10, reflecting significant growth expectations (the NASDAQ currently has a ratio of 3.2).

Changes made to index


Allocation as of April 2, 2017

Calvin Schmidt Synthetic Biology Index: April Update

Calvin Schmidt Synthetic Biology Index: February Update